Literature DB >> 24555604

Evaluation of low-dose CT angiography with model-based iterative reconstruction after endovascular aneurysm repair of a thoracic or abdominal aortic aneurysm.

Neil J Hansen1, Ravi K Kaza, Katherine E Maturen, Peter S Liu, Joel F Platt.   

Abstract

OBJECTIVE: The objective of our study was to evaluate image quality and overall adequacy of low-dose CT angiography (CTA) with model-based iterative reconstruction (MBIR) in patients who had undergone endovascular aneurysm repair (EVAR) of a thoracic or abdominal aortic aneurysm.
MATERIALS AND METHODS: Thirty patients, all of whom had undergone standard-dose CTA performed previously with adaptive statistical iterative reconstruction (ASIR), underwent low-dose CTA for surveillance after EVAR. Two radiologists randomly evaluated both studies, and quality parameters were assessed. The maximal aneurysm diameter was measured, and the images were evaluated to see whether an endoleak was present. The image noise and contrast-to-noise ratio (CNR) were measured. The volume CT dose index and dose-length product were recorded.
RESULTS: The mean image score for low-dose CTA was acceptable to very good in all categories of assessment. There was no significant difference between low-dose CTA and standard-dose CTA in the evaluation of the stent lumen. Subjective assessments of stent configuration, aneurysm outline, aortic branch vessel outline, overall adequacy of vascular imaging, and overall adequacy of solid organ imaging were superior on standard-dose CTA. Interobserver agreement for endoleak detection was higher for low-dose CTA. There was no significant difference in the mean aneurysm diameter between the two readers on low-dose CTA and standard-dose CTA. The effective radiation dose for low-dose CTA was lower than standard-dose CTA during both the arterial (mean, 4.4 vs 16.2 mSv, respectively) and the delayed (2.4 vs 6.7 mSv) phase acquisitions. The measured image noise was lower (14.7 vs 19.3 HU) and CNR was higher (25.6 vs 17.1) on the low-dose CTA studies than on the standard-dose CTA studies.
CONCLUSION: Low-dose CTA with MBIR enables up to 73% dose reduction as compared with CTA performed with ASIR while maintaining diagnostic adequacy for CTA surveillance of patients who have undergone EVAR of a thoracic or abdominal aortic aneurysm.

Entities:  

Mesh:

Year:  2014        PMID: 24555604     DOI: 10.2214/AJR.13.11286

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

1.  Knowledge-based iterative model reconstruction: comparative image quality and radiation dose with a pediatric computed tomography phantom.

Authors:  Young Jin Ryu; Young Hun Choi; Jung-Eun Cheon; Seongmin Ha; Woo Sun Kim; In-One Kim
Journal:  Pediatr Radiol       Date:  2015-11-06

Review 2.  Surveillance Imaging Following Endovascular Aneurysm Repair.

Authors:  Nirnimesh Pandey; Harold I Litt
Journal:  Semin Intervent Radiol       Date:  2015-09       Impact factor: 1.513

Review 3.  Complications of endovascular aneurysm repair of the thoracic and abdominal aorta: evaluation and management.

Authors:  Dania Daye; T Gregory Walker
Journal:  Cardiovasc Diagn Ther       Date:  2018-04

4.  Imaging studies in pediatric fibromuscular dysplasia (FMD): a single-center experience.

Authors:  Robert Louis; Daniella Levy-Erez; Anne Marie Cahill; Kevin E Meyers
Journal:  Pediatr Nephrol       Date:  2018-06-04       Impact factor: 3.714

Review 5.  Diagnostic imaging methods applied in long-term surveillance after EVAR. Will computed tomography angiography be replaced by other methods?

Authors:  Karolina Stefaniak; Michal Stanisic; Marcin Gabriel; Grzegorz Oszkinis
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-02-11       Impact factor: 1.426

6.  High-pitch, low-voltage and low-iodine-concentration CT angiography of aorta: assessment of image quality and radiation dose with iterative reconstruction.

Authors:  Yanguang Shen; Zhonghua Sun; Lei Xu; Yu Li; Nan Zhang; Zixu Yan; Zhanming Fan
Journal:  PLoS One       Date:  2015-02-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.